C. Schmid-Wirlitsch

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.

P. Bardin, D. Bredenbröker, E. V. van Schalkwyk, 2005, The Journal of allergy and clinical immunology.

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects

L. Boulet, P. O'Byrne, M. Duong, 2011, Respiratory research.

Efficacy and safety of roflumilast in the treatment of asthma.

E. Bateman, J. Izquierdo, P. Magyar, 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Roflumilast, a Phosphodiesterase 4 Inhibitor, Reduces Airway Hyperresponsiveness after Allergen Challenge

P. Bardin, D. Bredenbröker, P. Bardin, 2006, Respiration.

Long-term Safety of Roflumilast in the Treatment of Chronic Obstructive Pulmonary Disease

E. Bateman, H. Steffen, J. Noord, 2004 .